Lilly's oral weight‑loss launch
- The FDA granted speedy approval to Eli Lilly's oral weight-loss pill, and prescriptions surged in the drug's opening days. - Early data show more than 1,000 prescriptions and a reported heart‑safety success in a diabetes trial for Foundayo. - Despite demand, insurer and pharmacy‑benefit manager restrictions are limiting access and creating a reimbursement bottleneck for patients ( ).
Eli Lilly’s new weight-loss pill reached U.S. patients fast after an unusually rapid Food and Drug Administration review, and early prescriptions topped 1,000 in its first week. (fda.gov, finance.yahoo.com) The drug is Foundayo, also known as orforglipron, a once-daily glucagon-like peptide-1 pill for adults with obesity or overweight plus a related medical condition. The Food and Drug Administration approved it on April 1, 2026, 50 days after filing and 294 days before its original January 20, 2027 target date. (fda.gov, accessdata.fda.gov) Glucagon-like peptide-1 drugs mimic a gut hormone that helps people feel full and lowers blood sugar; most big sellers in the category have been injections. Lilly says Foundayo is the only weight-loss GLP-1 pill that can be taken any time of day without food or water restrictions. (fda.gov, investor.lilly.com) In Lilly’s ATTAIN-1 study, patients who stayed on the highest dose lost an average of 27.3 pounds, or 12.4% of body weight, versus 2.2 pounds on placebo. Lilly began taking prescriptions immediately through LillyDirect, with shipping starting April 6 and broader retail pharmacy availability following. (investor.lilly.com) The opening demand was measurable within days. Reuters reported that analysts citing IQVIA data counted 1,390 U.S. prescriptions in the week ended April 10. (finance.yahoo.com, pharmexec.com) Lilly added another data point on April 16, when it said Foundayo met the main heart-safety goal in the Phase 3 ACHIEVE-4 diabetes trial against insulin glargine. Lilly said the study enrolled more than 2,700 people across 15 countries and showed a non-inferior rate of major adverse cardiovascular events over 104 weeks. (investor.lilly.com) The company also said ACHIEVE-4 showed a 16% lower risk of the broader MACE-4 composite and a 57% lower risk of all-cause death, though the death result was from a pre-planned analysis and the release said some findings were not controlled for multiplicity. Lilly said it plans to file Foundayo for type 2 diabetes by the end of the second quarter. (investor.lilly.com) The access problem has not disappeared with a pill. Lilly says Foundayo starts at $25 a month for commercially insured patients and $149 for self-pay through its launch program, but coverage for obesity drugs remains uneven and often depends on prior authorization or employer plan design. (investor.lilly.com, npr.org) That squeeze is hitting the broader obesity-drug market, not just Lilly’s new pill. An NPR report carried by public-radio affiliates said GoodRx found 12 million people lost coverage for Zepbound and another 12 million lost coverage for Wegovy from 2025 to 2026. (wskg.org, gpb.org) For patients, that means the launch is testing two separate questions at once: whether people want an easier-to-take GLP-1, and whether insurers and pharmacy-benefit managers will pay for it. The first answer arrived in the first week; the second is still being negotiated claim by claim. (finance.yahoo.com, npr.org)
